Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors
1
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA
2
Department of Chemistry, University of Iowa, Iowa City, IA 52242, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Robert M. Coates
Molecules 2017, 22(6), 886; https://doi.org/10.3390/molecules22060886
Received: 4 April 2017 / Revised: 24 May 2017 / Accepted: 24 May 2017 / Published: 27 May 2017
(This article belongs to the Special Issue Isoprenoid Biosynthesis)
The enzyme geranylgeranyl diphosphate synthase (GGDPS) catalyzes the synthesis of the 20-carbon isoprenoid geranylgeranyl diphosphate (GGPP). GGPP is the isoprenoid donor for protein geranylgeranylation reactions catalyzed by the enzymes geranylgeranyl transferase (GGTase) I and II. Inhibitors of GGDPS result in diminution of protein geranylgeranylation through depletion of cellular GGPP levels, and there has been interest in GGDPS inhibitors as potential anti-cancer agents. Here we discuss recent advances in the development of GGDPS inhibitors, including insights gained by structure-function relationships, and review the preclinical data that support the continued development of this novel class of drugs.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Haney, S.L.; Wills, V.S.; Wiemer, D.F.; Holstein, S.A. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors. Molecules 2017, 22, 886.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
